{"id":"ramucirumab-dp-imc-1121b","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Hypertension"},{"rate":"10-20%","effect":"Fatigue"},{"rate":"5-10%","effect":"Headache"},{"rate":"5-10%","effect":"Nausea"},{"rate":"5-10%","effect":"Diarrhea"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By binding to VEGFR2, Ramucirumab DP prevents the activation of downstream signaling pathways that promote angiogenesis, thereby inhibiting tumor growth and metastasis. This mechanism of action is particularly relevant in the treatment of various cancers.","oneSentence":"Ramucirumab DP is a monoclonal antibody that targets and binds to vascular endothelial growth factor receptor 2 (VEGFR2), inhibiting angiogenesis.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:31:15.211Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Non-small cell lung cancer, gastric cancer, and other solid tumors"}]},"trialDetails":[{"nctId":"NCT06616584","phase":"PHASE2, PHASE3","title":"Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)","status":"RECRUITING","sponsor":"SWOG Cancer Research Network","startDate":"2025-05-22","conditions":"Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8","enrollment":378},{"nctId":"NCT05096663","phase":"PHASE2, PHASE3","title":"Testing the Use of Combination Immunotherapy Treatment (N-803 [ALT-803] Plus Pembrolizumab) Against the Usual Treatment for Advanced Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)","status":"ACTIVE_NOT_RECRUITING","sponsor":"SWOG Cancer Research Network","startDate":"2022-03-15","conditions":"Advanced Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Stage III Lung Cancer AJCC v8","enrollment":82},{"nctId":"NCT04267913","phase":"PHASE2","title":"Testing of TAK228 (MLN0128, Sapanisertib) Plus Docetaxel to the Usual Standard of Care for Advanced Squamous Cell Lung Cancer (A Lung-MAP Treatment Trial)","status":"WITHDRAWN","sponsor":"SWOG Cancer Research Network","startDate":"2020-09-05","conditions":"Lung Squamous Cell Carcinoma, Recurrent Lung Carcinoma, Stage IV Lung Cancer AJCC v8","enrollment":""},{"nctId":"NCT01170663","phase":"PHASE3","title":"A Study of Paclitaxel With or Without Ramucirumab (IMC-1211B) in Metastatic Gastric Adenocarcinoma","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2010-12","conditions":"Gastric Cancer","enrollment":665},{"nctId":"NCT01282463","phase":"PHASE2","title":"Study of Ramucirumab or Icrucumab (IMC-18F1) With Docetaxel or Docetaxel Alone as Second-Line Therapy in Participants With Bladder,Urethra, Ureter, or Renal Pelvis Carcinoma","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2011-04","conditions":"Carcinoma of Urinary Tract, Urethral Carcinoma, Carcinoma of Ureter","enrollment":148},{"nctId":"NCT01234402","phase":"PHASE2","title":"Study of Icrucumab (IMC-18F1) or Ramucirumab Drug Product (DP) in Combination With Capecitabine or Capecitabine on Previously Treated Breast Cancer Patients","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2011-03","conditions":"Breast Cancer","enrollment":153},{"nctId":"NCT01140347","phase":"PHASE3","title":"A Study of Ramucirumab (IMC-1121B) Drug Product (DP) and Best Supportive Care (BSC) Versus Placebo and BSC as 2nd-Line Treatment in Participants With Hepatocellular Carcinoma After 1st-Line Therapy With Sorafenib","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2010-10","conditions":"Hepatocellular Carcinoma","enrollment":565}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["IMC-1121B","LY3009806"],"phase":"phase_3","status":"active","brandName":"Ramucirumab DP (IMC-1121B)","genericName":"Ramucirumab DP (IMC-1121B)","companyName":"Eli Lilly and Company","companyId":"eli-lilly","modality":"Biologic","firstApprovalDate":"","aiSummary":"Ramucirumab DP is a monoclonal antibody that targets and binds to vascular endothelial growth factor receptor 2 (VEGFR2), inhibiting angiogenesis. Used for Non-small cell lung cancer, gastric cancer, and other solid tumors.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}